Biomedical subjects

R Y Ting

Publications and source records attributed to R Y Ting.

3 recordsLinked to original sources

PubMed1988

Enzyme activity gel analysis of human immunodeficiency virus reverse transcriptase.

An activity gel analysis was performed in order to examine the catalytically active component of human immunodeficiency virus (HIV) reverse transcriptase in purified enzyme preparations and HIV-infected cell extracts. Immunoaffinity purified HIV reverse transcriptase contains two proteins with molecular weights 66,000 and 51,000 in approximately equal proportions. After denaturing polyacrylamide gel electrophoresis and removal of sodium dodecyl sulfate, the p66 component of reverse transcriptase was sufficient for both DNA- and RNA-directed DNA synthesis. No DNA synthetic activity of p51 was observed. Recovery of p66 catalytic activity was approximately 10% that of DNA polymerase beta, and the density of the autoradiographic band corresponding to p66 was linear with enzyme concentration. No additional HIV-specific DNA polymerases besides p66 were observed in HIV-infected H9 cell extracts.

DNA Polymerase I↗

PubMed1987

Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs.

Using affinity purified human immunodeficiency virus (HIV) reverse transcriptase the reaction assay conditions were determined. The optimum incorporation of dTMP into the (rA)n(dT)10 template with HIV reverse transcriptase required 6 mM MgCl2 and 80 mM KCl. The template specificity of HIV reverse transcriptase is quite different from those of the human gamma-polymerase-associated reverse transcriptase or avian virus reverse transcriptase. The preferential inhibition of HIV reverse transcriptase as compared to human gamma-reverse transcriptase was observed with several nucleoside analog triphosphates. The Ki values for thymidine triphosphate analogs with HIV reverse transcriptase ranged from 5 to 13 nM with decreasing effectiveness for 3'-fluoro greater than 3'-amino greater than 2',3'-dideoxy greater than 3'-azido groups. This study provides information on the structure activity relationships of the triphosphate analogs inhibitory effects on HIV reverse transcriptase versus human gamma-polymerase-associated reverse transcriptase, and the possible mechanisms of action of 3' azido thymidine and the 2',3'-dideoxynucleosides, and also identifies other nucleoside analogs for possible development as inhibitors of HIV.

Deoxyguanine Nucleotides↗

PubMed1980

Follow-up studies of very low birth weight infants (1,250 grams or less) born and treated within a perinatal center.

The growth and development of inborn very low birth weight infants was evaluated in 50 of 60 survivors from 132 babies weighing less than or equal to 1,250 gm born July 1974 to December 1977. Mean +/- SE birth weight and gestation was 1,066 +/- 19.3 gm and 29.5 +/- 0.3 weeks, respectively, with 13 infants small-for-gestational age. Of the survivors, 26% weighed less than or equal to 1,000 gm. Male to female ratio was 1:1.4. Apgar scores less than or equal to 5 at five minutes occurred in 16% of the infants. Respiratory distress syndrome occurred in 56%, but only 10% (5/50) required mechanical ventilation. At 1 year, 46% small for gestational age (SGA) and 8% appropriate for gestational age (AGA) infants were less than the third percentile for weight. Major neurologic abnormality occurred in three infants (6%), one of whom is also blind. Grade V retrolental fibroplasia occurred in two others. Severe developmental delay (development quotient < 80, Gesell) occurred in these five infants and two other neurologically normal babies. Of 15 infants weighing less than or equal to 1,000 gm, two had major handicaps. Eight percent of the AGA infants and 30% of the SGA infants had major handicaps. These data indicate that infants born and treated in a perinatal center have a decreased incidence of asphyxia and severe respiratory distress syndrome and that the incidence of major handicaps is reduced, especially in the appropriate for gestational age baby.

Developmental Disabilities↗